RxDoctor Payments Data

Jane Loman, MD

Ophthalmology · Oakland, CANPI 1346274024

Payments from drug & device makers

$6,601in general payments, 2019–2025

Across 247 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$1K
  • Glaukos Corporation$869
  • NEW World Medical,inc.$564
  • Oyster Point Pharma, Inc.$545
  • Bausch & Lomb Americas Inc.$353
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$6,49998%
  • Education$180%
  • Gifts$190%
  • Entertainment$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,601 in reported general payments places this provider in the 75th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$454,998
Medicare patients
855
Services billed
3,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost156$67,964
VyzultaLatanoprostene Bunod110$50,466
XiidraLifitegrast47$41,425
Alphagan PBrimonidine Tartrate83$29,552
RestasisCyclosporine32$27,486
RocklatanNetarsudil Mesylat/Latanoprost47$23,507
SimbrinzaBrinzolamide/Brimonidine Tart62$14,638
TyrvayaVarenicline Tartrate18$12,264
CombiganBrimonidine Tartrate/Timolol26$11,905
Brimonidine Tartrate197$11,426
IyuzehLatanoprost/Pf29$11,151
MieboPerfluorohexyloctane/Pf14$10,382
TafluprostTafluprost/Pf67$9,965
Prednisolone Acetate183$9,574
RhopressaNetarsudil Mesylate23$9,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan, Restasis Multidose$1,403$145,188310 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo$353$102,273171 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$283$32,78370 claims
AlconSimbrinza, Azopt$1,126$20,46178 claims
Oyster Point Pharma, Inc.Tyrvaya$545$12,26418 claims
Thea Pharma Inc.Iyuzeh$39$11,15129 claims
Akorn, Inc.Zioptan$24$4,95212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →